HSP90AA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, in AML and CML, HDAC inhibition leads to stronger binding of HSP90 to its inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), fostering HSP90 degradation.